Clinical benefits and recovery of delayed-type hypersensitivity in patients with AIDS-related complex treated with IMREG-1 or placebo

• Published in: International journal of immunopharmacology Vol. 13; no. 7; p. 999
• Main Authors: Fiala, M, Cone, L A, Sayre, J W
• Format: Journal Article
• Language: English
• Published: England 1991
• Subjects: Adult; AIDS-Related Complex - complications; AIDS-Related Complex - immunology; AIDS-Related Complex - therapy; Double-Blind Method; Humans; Hypersensitivity, Delayed; Immunotherapy; Lymphokines - adverse effects; Lymphokines - therapeutic use; Male; Opportunistic Infections - prevention & control; Pneumonia, Pneumocystis - prevention & control; Sarcoma, Kaposi - prevention & control

IMREG-1, an immunomodulatory biological therapeutic, was studied in a placebo-controlled, double-blind, six-month trial in 45 anergic patients with AIDS-related complex (ARC) and 4 with Kaposi's sarcoma, which was followed by compassionate IMREG-1 administration to all subjects. The IMREG-1 gro...